{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:25:58Z","timestamp":1762899958624,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1IO1BX000803","IK2 BX004360"],"award-info":[{"award-number":["1IO1BX000803","IK2 BX004360"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F31CA228373","T32CA117846","T32CA117846"],"award-info":[{"award-number":["F31CA228373","T32CA117846","T32CA117846"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012875","name":"Cancer Institute, University of Cincinnati","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s10549-020-05653-y","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T16:41:58Z","timestamp":1588005718000},"page":"529-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients"],"prefix":"10.1007","volume":"181","author":[{"given":"Brian G.","family":"Hunt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina A.","family":"Wicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Bourn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyse E.","family":"Lower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinita","family":"Takiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3572-4642","authenticated-orcid":false,"given":"Susan E.","family":"Waltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"5653_CR1","unstructured":"ACS (2017) Breast Cancer Facts & Figures 2017\u20132018"},{"key":"5653_CR2","unstructured":"ACS (2019) Cancer Facts & Figures"},{"issue":"2","key":"5653_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ijc.31914","volume":"144","author":"MC van Maaren","year":"2019","unstructured":"van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML, Poortmans PMP, Siesling S (2019) Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer 144(2):263\u2013272. https:\/\/doi.org\/10.1002\/ijc.31914","journal-title":"Int J Cancer"},{"issue":"6","key":"5653_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/bcr1339","volume":"7","author":"E Paci","year":"2005","unstructured":"Paci E, Duffy S (2005) Overdiagnosis and overtreatment of breast cancer: overdiagnosis and overtreatment in service screening. Breast Cancer Res 7(6):266\u2013270. https:\/\/doi.org\/10.1186\/bcr1339","journal-title":"Breast Cancer Res"},{"issue":"4","key":"5653_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000149357","volume":"3","author":"M Schmidt","year":"2008","unstructured":"Schmidt M (2008) Node-Negative Breast Cancer: Which Patients Should Be Treated? Breast Care (Basel) 3(4):237\u2013243. https:\/\/doi.org\/10.1159\/000149357","journal-title":"Breast Care (Basel)"},{"key":"5653_CR6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","volume":"380","author":"JA Sparano","year":"2019","unstructured":"Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer JC, Dees EC, Goetz MP (2019) Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 380:2395\u20132405","journal-title":"N Engl J Med"},{"key":"5653_CR7","volume-title":"Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue","author":"J Esteban","year":"2003","unstructured":"Esteban J, Baker J, Cronin M, Liu M, Llamas M, Walker M, Mena R, Shak S (2003) Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue. SienceOpen, Burlington"},{"key":"5653_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(08)00001-8","volume":"100","author":"PK Wagh","year":"2008","unstructured":"Wagh PK, Peace BE, Waltz SE (2008) Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100:1\u201333","journal-title":"Adv Cancer Res"},{"issue":"9","key":"5653_CR9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1517\/14728222.2012.710200","volume":"16","author":"NM Benight","year":"2012","unstructured":"Benight NM, Waltz SE (2012) Ron receptor tyrosine kinase signaling as a therapeutic target. Expert Opin Ther Targets 16(9):921\u2013931. https:\/\/doi.org\/10.1517\/14728222.2012.710200","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"5653_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2217\/14796694.3.4.441","volume":"3","author":"MA Leonis","year":"2007","unstructured":"Leonis MA, Thobe MN, Waltz SE (2007) Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol 3(4):441\u2013448. https:\/\/doi.org\/10.2217\/14796694.3.4.441","journal-title":"Future Oncol"},{"issue":"6","key":"5653_CR11","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-12-2474","volume":"73","author":"D Gurusamy","year":"2013","unstructured":"Gurusamy D, Gray JK, Pathrose P, Kulkarni RM, Finkleman FD, Waltz SE (2013) Myeloid-specific expression of ron receptor kinase promotes prostate tumor growth. Cancer Res 73(6):1752","journal-title":"Cancer Res"},{"issue":"18","key":"5653_CR12","doi-asserted-by":"publisher","first-page":"7570","DOI":"10.1073\/pnas.0702095104","volume":"104","author":"AL Welm","year":"2007","unstructured":"Welm AL, Sneddon JB, Taylor C, Nuyten DSA, Van De Vijver MJ, Hasegawa BH, Bishop JM (2007) The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci 104(18):7570\u20137575","journal-title":"Proc Natl Acad Sci"},{"issue":"28","key":"5653_CR13","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1038\/s41388-019-0811-9","volume":"38","author":"ML Babicky","year":"2019","unstructured":"Babicky ML, Harper MM, Chakedis J, Cazes A, Mose ES, Jaquish DV, French RP, Childers B, Alakus H, Schmid MC, Foubert P, Miyamoto J, Holman PJ, Walterscheid ZJ, Tang C-M, Varki N, Sicklick JK, Messer K, Varner JA, Waltz SE, Lowy AM (2019) MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages. Oncogene 38(28):5599\u20135611. https:\/\/doi.org\/10.1038\/s41388-019-0811-9","journal-title":"Oncogene"},{"issue":"9","key":"5653_CR14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.neo.2018.07.003","volume":"20","author":"NE Brown","year":"2018","unstructured":"Brown NE, Paluch AM, Nashu MA, Komurov K, Waltz SE (2018) Tumor cell autonomous RON receptor expression promotes prostate cancer growth under conditions of androgen deprivation. Neoplasia 20(9):917\u2013929","journal-title":"Neoplasia"},{"key":"5653_CR15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19441","author":"SJ Ruiz-Torres","year":"2017","unstructured":"Ruiz-Torres SJ, Benight NM, Karns RA, Lower EE, Guan J-L, Waltz SE (2017) HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical \u03b2-catenin signaling. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.19441","journal-title":"Oncotarget"},{"issue":"34","key":"5653_CR16","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1038\/onc.2011.86","volume":"30","author":"PK Wagh","year":"2011","unstructured":"Wagh PK, Gray JK, Zinser GM, Vasiliauskas J, James L, Monga SP, Waltz SE (2011) \u03b2-Catenin is required for Ron receptor-induced mammary tumorigenesis. Oncogene 30(34):3694\u20133704","journal-title":"Oncogene"},{"issue":"6","key":"5653_CR17","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1210\/en.2011-1543","volume":"153","author":"PK Wagh","year":"2012","unstructured":"Wagh PK, Zinser GM, Gray JK, Shrestha A, Waltz SE (2012) Conditional deletion of \u03b2-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis. Endocrinology 153(6):2735\u20132746","journal-title":"Endocrinology"},{"key":"5653_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1158\/0008-5472.CAN-09-0761","volume":"70","author":"J Logan-Collins","year":"2010","unstructured":"Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM (2010) Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res 70:1130\u20131140","journal-title":"Cancer Res"},{"issue":"13","key":"5653_CR19","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1158\/0008-5472.CAN-06-4128","volume":"67","author":"RM Thomas","year":"2007","unstructured":"Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM (2007) The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67(13):6075\u20136082. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4128","journal-title":"Cancer Res"},{"issue":"24","key":"5653_CR20","doi-asserted-by":"publisher","first-page":"11967","DOI":"10.1158\/0008-5472.CAN-06-2473","volume":"66","author":"GM Zinser","year":"2006","unstructured":"Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE (2006) Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with \u03b2-catenin activation. Cancer Res 66(24):11967\u201311974","journal-title":"Cancer Res"},{"key":"5653_CR21","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1038\/sj.onc.1201812","volume":"16","author":"P Maggiora","year":"1998","unstructured":"Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM (1998) Overexpression of the RON gene in human breast carcinoma. Oncogene 16:2927\u20132933","journal-title":"Oncogene"},{"issue":"9","key":"5653_CR22","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2174\/138945010792006825","volume":"11","author":"KL Kretschmann","year":"2010","unstructured":"Kretschmann KL, Eyob H, Buys SS, Welm AL (2010) The macrophage stimulating protein\/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Curr Drug Targets 11(9):1157\u20131168. https:\/\/doi.org\/10.2174\/138945010792006825","journal-title":"Curr Drug Targets"},{"issue":"1","key":"5653_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1476-4598-11-2","volume":"11","author":"AM Marshall","year":"2012","unstructured":"Marshall AM, McClaine RJ, Gurusamy D, Gray JK, Lewnard KE, Khan SA, Waltz SE (2012) Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice. Mol Cancer 11(1):2. https:\/\/doi.org\/10.1186\/1476-4598-11-2","journal-title":"Mol Cancer"},{"issue":"6","key":"5653_CR24","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/1078-0432.CCR-04-1761","volume":"11","author":"W-Y Lee","year":"2005","unstructured":"Lee W-Y, Chen HHW, Chow N-H, Su W-C, Lin P-W, Guo H-R (2005) Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 11(6):2222\u20132228","journal-title":"Clin Cancer Res"},{"issue":"374","key":"5653_CR25","doi-asserted-by":"publisher","first-page":"eaai9338","DOI":"10.1126\/scitranslmed.aai9338","volume":"9","author":"K Andrade","year":"2017","unstructured":"Andrade K, Fornetti J, Zhao L, Miller SC, Randall RL, Anderson N, Waltz SE, McHale M, Welm AL (2017) RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis. Sci Transl Med 9(374):eaai9338","journal-title":"Sci Transl Med"},{"issue":"19","key":"5653_CR26","doi-asserted-by":"publisher","first-page":"17445","DOI":"10.18632\/oncotarget.3641","volume":"6","author":"NM Benight","year":"2015","unstructured":"Benight NM, Wagh PK, Zinser GM, Peace BE, Stuart WD, Vasiliauskas J, Pathrose P, Starnes SL, Waltz SE (2015) HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses. Oncotarget 6(19):17445","journal-title":"Oncotarget"},{"key":"5653_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/2159-8290.CD-12-0480","volume":"3","author":"H Eyob","year":"2013","unstructured":"Eyob H, Ekiz HA, DeRose YS, Waltz SE, Williams MA, Welm AL (2013) Inhibition of Ron kinase blocks conversion of micrometastases to overt metastases by boosting anti-tumor immunity. Cancer Discov 3:751\u2013760","journal-title":"Cancer Discov"},{"issue":"8","key":"5653_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1593\/neo.10476","volume":"12","author":"RJ McClaine","year":"2010","unstructured":"McClaine RJ, Marshall AM, Wagh PK, Waltz SE (2010) Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia 12(8):650\u2013658","journal-title":"Neoplasia"},{"issue":"4","key":"5653_CR29","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1158\/0008-5472.CAN-03-3580","volume":"65","author":"BE Peace","year":"2005","unstructured":"Peace BE, Toney-Earley K, Collins MH, Waltz SE (2005) Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 65(4):1285\u20131293","journal-title":"Cancer Res"},{"issue":"3","key":"5653_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","volume":"123","author":"B Gy\u00f6rffy","year":"2010","unstructured":"Gy\u00f6rffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3):725\u2013731","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"5653_CR31","doi-asserted-by":"publisher","first-page":"9162","DOI":"10.1158\/0008-5472.CAN-06-0283","volume":"66","author":"JM Otoole","year":"2006","unstructured":"Otoole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ (2006) Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66(18):9162\u20139170","journal-title":"Cancer Res"},{"issue":"2","key":"5653_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/onc.2009.331","volume":"29","author":"MN Thobe","year":"2010","unstructured":"Thobe MN, Gurusamy D, Pathrose P, Waltz SE (2010) The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene 29(2):214","journal-title":"Oncogene"},{"issue":"8","key":"5653_CR33","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/jco.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160\u20131167. https:\/\/doi.org\/10.1200\/jco.2008.18.1370","journal-title":"J Clin Oncol"},{"issue":"2","key":"5653_CR34","doi-asserted-by":"publisher","first-page":"e000247","DOI":"10.1136\/bmjopen-2011-000247","volume":"1","author":"C Stapelkamp","year":"2011","unstructured":"Stapelkamp C, Holmberg L, Tataru D, M\u00f8ller H, Robinson D (2011) Predictors of early death in female patients with breast cancer in the UK: a cohort study. BMJ Open 1(2):e000247\u2013e000247. https:\/\/doi.org\/10.1136\/bmjopen-2011-000247","journal-title":"BMJ Open"},{"issue":"4","key":"5653_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5858\/arpa.2014-0080-ED","volume":"139","author":"PP Yu","year":"2015","unstructured":"Yu PP, Hoffman MA, Hayes DF (2015) Biomarkers and oncology: the path forward to a learning health system. Arch Pathol Lab Med 139(4):451\u2013456. https:\/\/doi.org\/10.5858\/arpa.2014-0080-ED","journal-title":"Arch Pathol Lab Med"},{"issue":"34","key":"5653_CR36","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1200\/JCO.2012.42.6858","volume":"30","author":"LM McShane","year":"2012","unstructured":"McShane LM, Hayes DF (2012) Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol 30(34):4223","journal-title":"J Clin Oncol"},{"issue":"21","key":"5653_CR37","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/jnci\/djp335","volume":"101","author":"RM Simon","year":"2009","unstructured":"Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101(21):1446\u20131452","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"5653_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1741-7015-10-51","volume":"10","author":"DG Altman","year":"2012","unstructured":"Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 10(1):51","journal-title":"BMC Med"},{"key":"5653_CR39","volume-title":"Evolution of translational omics: lessons learned and the path forward","author":"GS Omenn","year":"2012","unstructured":"Omenn GS, Nass SJ, Micheel CM (2012) Evolution of translational omics: lessons learned and the path forward. National Academies Press, Washington, DC"},{"issue":"8","key":"5653_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrc.2016.56","volume":"16","author":"AJ Vargas","year":"2016","unstructured":"Vargas AJ, Harris CC (2016) Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer 16(8):525","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"5653_CR41","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1038\/onc.2014.173","volume":"34","author":"LMP Vinnedge","year":"2015","unstructured":"Vinnedge LMP, Benight NM, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz SE, Wells SI (2015) The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Oncogene 34(18):2325\u20132336. https:\/\/doi.org\/10.1038\/onc.2014.173","journal-title":"Oncogene"},{"issue":"8","key":"5653_CR42","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1593\/neo.10476","volume":"12","author":"RJ McClaine","year":"2010","unstructured":"McClaine RJ, Marshall AM, Wagh PK, Waltz SE (2010) Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia (New York, NY) 12(8):650\u2013658. https:\/\/doi.org\/10.1593\/neo.10476","journal-title":"Neoplasia (New York, NY)"},{"key":"5653_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41523-018-0091-5","volume":"4","author":"N Faham","year":"2018","unstructured":"Faham N, Zhao L, Welm AL (2018) mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. NPJ Breast Cancer 4:36\u201336. https:\/\/doi.org\/10.1038\/s41523-018-0091-5","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"5653_CR44","first-page":"256","volume":"4","author":"N Goossens","year":"2015","unstructured":"Goossens N, Nakagawa S, Sun X, Hoshida Y (2015) Cancer biomarker discovery and validation. Transl Cancer Res 4(3):256","journal-title":"Transl Cancer Res"},{"key":"5653_CR45","first-page":"1707","volume":"9","author":"J-Y Sun","year":"2016","unstructured":"Sun J-Y, Wu S-G, Li F-Y, Lin H-X, He Z-Y (2016) Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study. OncoTargets Ther 9:1707","journal-title":"OncoTargets Ther"},{"issue":"12","key":"5653_CR46","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s00432-017-2514-3","volume":"143","author":"A Caldarella","year":"2017","unstructured":"Caldarella A, Barchielli A (2017) Prognostic role of progesterone receptor expression in a population-based analysis. J Cancer Res Clin Oncol 143(12):2505\u20132509","journal-title":"J Cancer Res Clin Oncol"},{"key":"5653_CR47","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s12094-019-02149-0","volume":"22","author":"N Wu","year":"2019","unstructured":"Wu N, Fu F, Chen L, Lin Y, Yang P, Wang C (2019) Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis. Clin Transl Oncol 22:474\u2013485","journal-title":"Clin Transl Oncol"},{"key":"5653_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/bjs.11347","volume":"107","author":"M Boland","year":"2019","unstructured":"Boland M, Ryan \u00c9, Dunne E, Aherne T, Bhatt N, Lowery A (2019) Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer. Br J Surg 107:33\u201344","journal-title":"Br J Surg"},{"key":"5653_CR49","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2217\/bmm-2019-0209","volume":"13","author":"S-G Wu","year":"2019","unstructured":"Wu S-G, Zhang W-W, Wang J, Lian C-L, Sun J-Y, Chen Y-X, He Z-Y (2019) Progesterone receptor status and tumor grade predict the 21-gene recurrence score of invasive lobular breast cancer. Biomark Med 13:1005\u20131012","journal-title":"Biomark Med"},{"issue":"1","key":"5653_CR50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12885-015-1121-4","volume":"15","author":"SY Bae","year":"2015","unstructured":"Bae SY, Kim S, Lee JH, Lee H-c, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ (2015) Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer 15(1):138. https:\/\/doi.org\/10.1186\/s12885-015-1121-4","journal-title":"BMC Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05653-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:49:53Z","timestamp":1619484593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05653-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["5653"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05653-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"9 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We declare that there are no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Retrospective and archived sample studies presented herein comply with ethical standards implemented by the University of Cincinnati according to the specific requirements for human subjects testing in the United States.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Human participants: Samples obtained from human subjects were anonymized and de-identified prior to our acquisitionAnimals were not used in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving Human Participants and\/or Animals"}},{"value":"As is common practice at the University of Cincinnati and the Cooperative Human Tissue Network, Institutional Review Board (IRB) review took place and IRB protocol deemed unnecessary due to the anonymized and de-identified nature prior to acquisition of samples.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}